The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
5-Fluorouracil: mechanisms of action and clinical strategies
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“In vitro studies have reported that loss of p53 function reduces cellular sensitivity to 5-F”
Clinical Pharmacology of 5-Fluorouracil
Diasio, R. B., & Harris, B. E. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916040-00002 · Cited by 969 · cited 1×
“cgi?l=1806">DPD ), which converts 5-FU to dihydrofluorouracil (DHFU”
Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients
Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N. C., Lynch, H. T., Watson, P., Jass, J. R., Dunlop, M., Wyllie, A., Peltomäki, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-169 · Cited by 945 · cited 1×
“gov/htbin-post/Omim/dispmim?114500">hereditary non-polyposis colon cancer (HNPCC”
Role of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863 · cited 1×
“It has been shown that disrupting both alleles of TP53 or BAX in a colon cancer cell line made the cells strikingly resistant to apoptosis induced by 5-FU compared with the parental lin”
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Johnston, P. G., Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., & Leichman, L. (1995) · PubMed · Cited by 672
Self-citationMechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate
Santi, D. V., McHenry, C. S., & Sommer, H. (1974) · Biochemistry · doi:10.1021/bi00700a012 · Cited by 619 · cited 1×
“The 5-FU metabolite FdUMP binds to the nucleotide-binding site of TS, forming a stable TERNARY COMPLEX with the enzyme and CH 2 THF, thereby blocking binding of the normal substrate dUMP and inhibiting dTMP synthesi”
Lindahl, T. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.9.3649 · Cited by 601
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V, Xiong, Y.-P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., & Lenz, H.-J. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500012 · Cited by 571
Horie, N., Aiba, H., Oguro, K., Hojo, H., & Takeishi, K. (1995) · Cell Structure and Function · doi:10.1247/csf.20.191 · Cited by 547 · cited 1×
“The TS gene promoter is POLYMORPHIC and usually has either two (TSERa2) or three (TSERa3) 28-base-pair tandem-repeat sequence”
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
p21WAF1/Cip1: more than a break to the cell cycle?
Dotto, G. P. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00019-6 · Cited by 474
Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., & Bergh, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.173 · Cited by 381
Takebayashi, Y., Akiyama, S.-I., Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F., & Aikou, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1110 · Cited by 363 · cited 1×
“These contradictory findings might be explained by the fact that TP is also an angiogenic endothelial-cell growth factor and high TP expression in colorectal cancer has been correlated with worse prognosi”
Ahnen, D. J., Feigl, P., Quan, G., Fenoglio‐Preiser, C. M., Lovato, L., Bunn, P. A., Stemmerman, G. N., Wells, J. D., Macdonald, J. S., & Meyskens, F. L. (1998) · PubMed · Cited by 338
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323 · cited 1×
“Douillard and colleagues reported that UFT/LV produced equivalent response rates to 5-FU/LV and was a safer, more convenient treatmen”
Kawakami, K., Omura, K., Kanehira, E., & Watanabe, Y. (1999) · PubMed · Cited by 282
Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., & Boothman, D. A. (2001) · PubMed · Cited by 269
Metzger, R., Danenberg, K. D., Leichman, C. G., Salonga, D. S., Schwartz, E. L., Wadler, S., Lenz, H., Groshen, S. G., Leichman, L., & Danenberg, P. V. (1998) · PubMed · Cited by 259
Yoshioka, A., Tanaka, S., Hiraoka, O., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T., Garrett, C., & Wataya, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47554-0 · Cited by 252
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., & Allegra, C. J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.7.890 · Cited by 241
Johnston, P. G., Drake, J. C., Trepel, J. B., & Allegra, C. J. (1992) · PubMed · Cited by 226
Self-citationJohnson, M. R., Hageboutros, A., Wang, K., High, L. B., Smith, J. B., & Diasio, R. B. (1999) · PubMed · Cited by 225
Eda, H., Fujimoto, K., Watanabe, S.-I., Ura, M., Hino, A., Tanaka, Y., Wada, K., & Ishitsuka, H. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00735915 · Cited by 210
Lenz, H., Hayashi, K., Salonga, D. S., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, J. R., Groshen, S. G., Leichman, L. P., et al. (1998) · PubMed · Cited by 206
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
Marsh, S., McKay, J., Cassidy, J., & McLeod, H. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.383 · Cited by 205
Elsaleh, H., Powell, B. L., McCaul, K. A., Grieu, F., Grant, R., Joseph, D., & Iacopetta, B. J. (2001) · PubMed · Cited by 204
Zembutsu, H., Ohnishi, Y., Tsunoda, T., Furukawa, Y., Katagiri, T., Ueyama, Y., Tamaoki, N., Nomura, T., Kitahara, O., Yanagawa, R., et al. (2002) · PubMed · Cited by 201
Kihara, C., Tsunoda, T., Tanaka, T., Yamana, H., Furukawa, Y., Ono, K., Kitahara, O., Zembutsu, H., Yanagawa, R., Hirata, K., et al. (2001) · PubMed · Cited by 198
Rutman, R. J., CANTAROW, A., & Paschkis, K. E. (1954) · PubMed · Cited by 196
(1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.960 · Cited by 194
5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity.
Kufe, D. W., & Major, P. P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68695-3 · Cited by 191
Piedbois, P., Buyse, M. E., Blijham, G. H., et al. (1994) · Journal of Clinical Oncology · Cited by 191
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
Copur, S., Aiba, K., Drake, J. C., Allegra, C. J., & Chu, E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00067-a · Cited by 176 · cited 1×
“Gene amplification of TS with consequent increases in TS mRNA and protein has been observed in cell lines that are resistant to 5-FU and fluorodeoxyuridine (FUDR”
Wohlhueter, R. M., McIvor, R. S., & Plagemann, P. G. W. (1980) · Journal of Cellular Physiology · doi:10.1002/jcp.1041040305 · Cited by 171 · cited 1×
“It rapidly enters the cell using the same facilitated transport mechanism as uraci”
Chu, E., & Allegra, C. J. (1993) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-2488-5_16 · Cited by 166
DNA mismatch repair defects: role in colorectal carcinogenesis.
Jacob, S., & Praz, F. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01362-1 · Cited by 163 · cited 1×
“95 ) — whereas most sporadic MSI tumours are caused by transcriptional silencing of the MLH1 gene due to promoter methylatio”
Takechi, T., Nakano, K., Uchida, J., Mita, A., Toko, K., Takeda, S., Unemi, N., & Shirasaka, T. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050561 · Cited by 162
Zhan, Q., Chen, I. T., Antinore, M. J., & Fornace, A. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2768 · Cited by 158 · cited 1×
“cgi?l=1647"> GADD45α , the products of which induce cell-cycle arrest in response to DNA damag”
Thymineless death in colon carcinoma cells is mediated via Fas signaling
Houghton, J. A., Harwood, F. G., & Tillman, D. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8144 · Cited by 158 · cited 1×
“Several studies have indicated that cell death in response to thymidylate depletion occurs via the FAS signalling pathway in some human colon cancer cell line”
Capecitabine: a novel agent for the treatment of solid tumors
Johnston, P. G., & Kaye, S. B. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200109000-00001 · Cited by 156
Self-citationWadler, S., Lembersky, B. C., Atkins, M. B., Kirkwood, J. M., & Petrelli, N. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1806 · Cited by 153
Paradiso, A., Simone, G., Petroni, S., Leone, B. A., Vallejo, C. T., Lacava, J. A., Romero, A., Machiavelli, M. R., Lena, M. D., Allegra, C. J., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0964 · Cited by 148
Self-citationThe influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells.
Cadman, E. C., Heimer, R., & Benz, C. C. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69863-7 · Cited by 137
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Maxwell, P. J., Longley, D. B., Latif, T., Boyer, J. D., Allen, W. L., Lynch, M., McDermott, U., Harkin, D. P., Allegra, C. J., & Johnston, P. G. (2003) · PubMed · Cited by 135
Self-citationMechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.
Porter, D. J., Chestnut, W. G., Merrill, B. M., & Spector, T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42757-3 · Cited by 123
Johnson, M. R., Wang, K., & Diasio, R. B. (2002) · PubMed · Cited by 120
The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Ladner, R. D. (2001) · Current Protein and Peptide Science · doi:10.2174/1389203013380991 · Cited by 116 · cited 1×
“DNA damage due to dUTP misincorporation is highly dependent on the levels of the pyrophosphatase dUTPase, which limits intracellular accumulation of dUT”
Sommer, H., & Santi, D. V. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90601-9 · Cited by 111 · cited 1×
“The 5-FU metabolite FdUMP binds to the nucleotide-binding site of TS, forming a stable TERNARY COMPLEX with the enzyme and CH 2 THF, thereby blocking binding of the normal substrate dUMP and inhibiting dTMP synthesi”
Dolnick, B. J., & Cheng, Y. C. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34838-x · Cited by 110
Santi, D. V., & Hardy, L. W. (1987) · Biochemistry · doi:10.1021/bi00400a016 · Cited by 109
Peták, I., Tillman, D. M., & Houghton, J. A. (2000) · PubMed · Cited by 106
Glazer, R. I., & Lloyd, L. S. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14632-4 · Cited by 106
Evrard, A., Cuq, P., Ciccolini, J., Vian, L., & Cano, J. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690589 · Cited by 105
Wolmark, N., Smith, R. P., Fisher, B., Bryant, J., Hyams, D. M., Atkins, J., Dimitrov, N. S., Oishi, R. H., Prager, D., Fehrenbacher, L., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1810 · Cited by 101
Ghoshal, K., & Jacob, S. T. (1994) · PubMed · Cited by 101
Longley, D. B., Boyer, J. D., Allen, W. L., Latif, T., Ferguson, P., Maxwell, P. J., McDermott, U., Lynch, M., Harkin, D. P., & Johnston, P. G. (2002) · PubMed · Cited by 100
Self-citationThymidylate Synthase Pharmacogenetics in Colorectal Cancer
Marsh, S., & McLeod, H. L. (2001) · Clinical Colorectal Cancer · doi:10.3816/ccc.2001.n.018 · Cited by 95 · cited 1×
“More recently, genotyping of the TS promoter has been reported to divide colorectal cancer patients into those who receive a survival benefit from 5-FU-based chemotherapy and those who do no”
Adjei, A. A. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00010.x · Cited by 93
Houghton, J. A., Tillman, D. M., & Harwood, F. G. (1995) · PubMed · Cited by 93
Microsatellite Instability in Human Cancer: A Prognostic Marker for Chemotherapy?
Claij, N., & Riele, H. T. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4299 · Cited by 91
Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells
Chu, E., Voeller, D. M., Jones, K. L., Takechi, T., Maley, G. F., Maley, F., Segal, S., & Allegra, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.207 · Cited by 83
Seymour, M., Slevin, M. L., Kerr, D., Cunningham, D., James, R. D., Ledermann, J. A., Perren, T. J., McAdam, W. A., Harper, P., Neoptolemos, J. P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2280 · Cited by 81
Greco, F. A., Figlin, R. A., York, M., Einhorn, L. H., Schilsky, R. L., Marshall, E., Buys, S., Froimtchuk, M. J., Schüller, J., Schuchter, L. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2674 · Cited by 77
Park, J.-G., Collins, J. M., Gazdar, A. F., Allegra, C. J., Steinberg, S. M., Greene, R. F., & Kramer, B. S. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.19.1560 · Cited by 77
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Wang, W., Marsh, S., Cassidy, J., & McLeod, H. L. (2001) · PubMed · Cited by 76
Liang, J., Huang, K., Cheng, Y., Hsu, H., Cheng, A., Hsu, C., Yeh, K., Wang, S., & Chang, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1637 · Cited by 73 · cited 1×
“A number of clinical studies have found that p53 overexpression — a surrogate marker for TP53 mutations — correlated with resistance to 5-F”
Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil
Samuelsson, T. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.22.6139 · Cited by 71 · cited 1×
“In addition, rRNA, tRNA and snRNA all contain the modified base pseudouridine, and 5-FU has been shown to inhibit the post-transcriptional conversion of uridine to pseudouridine in these RNA specie”
5-Fluorouracil substitution alters pre-mRNA splicing in vitro.
Doong, S.-L., & Dolnick, B. J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68949-5 · Cited by 70
Radparvar, S., Houghton, P. J., & Houghton, J. A. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90046-4 · Cited by 69 · cited 1×
“POLYGLUTAMATION not only increases the cellular retention of CH 2 THF, but also enhances the stabilization of its ternary complex with TS and FdUM”
Houghton, J. A., Morton, C. L., Adkins, D. A., & Rahman, A. (1993) · PubMed · Cited by 69
Cao, D., Russell, R. L., Zhang, D., Leffert, J. J., & Pizzorno, G. (2002) · PubMed · Cited by 68
Grem, J. L., Jordan, E., Robson, M. E., Binder, R., Hamilton, J. M., Steinberg, S. M., Arbuck, S. G., Beveridge, R. A., Kales, A. N., & Miller, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1737 · Cited by 67
Aherne, G. W., Hardcastle, A., Raynaud, F. I., & Jackman, A. L. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00035-4 · Cited by 65 · cited 1×
“In addition, TS inhibition results in accumulation of dUMP, which might subsequently lead to increased levels of deoxyuridine triphosphate (dUTP”
Carrico, C. K., & Glazer, R. I. (1979) · PubMed · Cited by 60
Kanamaru, R., Kakuta, H., Sato, T., Ishioka, C., & Wakui, A. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00299864 · Cited by 58 · cited 1×
“It not only inhibits the processing of pre- rRNA into mature rRN”
Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.
Spector, T., Cao, S., Rustum, Y. M., Harrington, J. A., & Porter, D. J. T. (1995) · PubMed · Cited by 58
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole
Grem, J. L., & Fischer, P. H. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90084-3 · Cited by 57 · cited 1×
“This salvage pathway represents a potential mechanism of resistance to 5-F”
Takebe, N., Zhao, S.-C., Ural, A. U., Johnson, M. R., Banerjee, D., Diasio, R. B., & Bertino, J. R. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700393 · Cited by 57
Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
Benz, C. C., Tillis, T., Tattelman, E., & Cadman, E. C. (1982) · PubMed · Cited by 55
Edler, D., Blomgren, H., Allegra, C. J., Johnston, P. G., Lagerstedt, U., Magnusson, I., & Ragnhammar, P. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00306-7 · Cited by 53 · cited 1×
“Multiple clinical investigations have measured TS expression by immunohistochemistry and reverse-transcription PCR (RT-PCR) and have shown an improved response to 5-FU-based therapy in patients with low tumoral TS expressio”
Self-citationThe fas signaling pathway is functional in colon carcinoma cells and induces apoptosis.
Houghton, J. A., Harwood, F. G., Gibson, A. A., & Tillman, D. M. (1997) · PubMed · Cited by 50
Sequential methotrexate and 5-fluorouracil: mechanisms of synergy.
Bertino, J. R., Mini, E., & Dj, F. (1983) · PubMed · Cited by 47
Webley, S. D., Hardcastle, A., Ladner, R. D., Jackman, A. L., & Aherne, G. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1358 · Cited by 46
Eda, H., Fujimoto, K., Watanabe, S., Ishikawa, T., Ohiwa, T., Tatsuno, K., Tanaka, Y., & Ishitsuka, H. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb02876.x · Cited by 46 · cited 1×
“IFN-γ has been reported to upregulate the activities of the 5-FU anabolic enzymes TP and UP, resulting in enhanced 5-FU activatio”
Wright, J. E., Dreyfuss, A. I., el-Magharbel, I., Trites, D. H., Jones, S. M., Holden, S. A., Rosowsky, A., & Frei, E. (1989) · PubMed · Cited by 43
Patton, J. R. (1993) · Biochemistry · doi:10.1021/bi00085a027 · Cited by 43 · cited 1×
“and the assembly and activity of snRNA /protein complexes, thereby inhibiting splicing of pre- mRNA”
Voigt, W., Matsui, S., Yin, M.-B., Burhans, W. C., Minderman, H., & Rustum, Y. M. (1998) · PubMed · Cited by 42
Biochemical modulation: application of laboratory models to the clinic.
Leyland-Jones, B., & O'Dwyer, P. J. (1986) · PubMed · Cited by 42
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Nadal, J. C., van Groeningen, C. J., Pinedo, H. M., & Peters, G. J. (1988) · PubMed · Cited by 32
Matherly, L. H., Czajkowski, C. A., Muench, S. P., & Psiakis, J. T. (1990) · PubMed · Cited by 27
Randerath, K., Tseng, W.-C., Harris, J. S., & Lu, L. J. W. (1983) · Springer eBooks · doi:10.1007/978-3-642-81947-6_22 · Cited by 26
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells
Mitrovski, B., Pressacco, J., Mandelbaum, S., & Erlichman, C. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686631 · Cited by 26 · cited 1×
“In addition, TS inhibition results in accumulation of dUMP, which might subsequently lead to increased levels of deoxyuridine triphosphate (dUTP”
McSheehy, P., Prior, M., & Griffiths, J. R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.75 · Cited by 26
Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors
Gorlick, R. G., & Bertino, J. R. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_3 · Cited by 22
Inhibition by methotrexate of the stable incorporation of 5-fluorouracil into murine bone marrow DNA
Sawyer, R. C., Stolfi, R. L., Martin, D. S., & Balis, M. E. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90470-x · Cited by 7
Paradiso, A., Maiello, E., Ranieri, G., Galetta, D., Mangia, A., Giuliani, F., Zito, A., Montemurro, S., Johnston, G., & Colucci, G. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81631-2 · Cited by 2
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Self-citationModulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
“…and Scherle, 2006 5-fluorouracil (small molecule) DNA NOA Inhibits pyrimidine metabolism, incorporation in to DNA and RNA causes cell-cycle arrest Longley et al., 2003 ABT-737, ABT-263 (small molecule) BCL-XL, BCL-2 OA Bind to the BH3 pocket of Bcl-XL and inhibit its antiapoptotic function…”
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.